Director TitleAgeSince
Chairman 53 2022-01-20
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.23%-0.59%+54.39%+120.28% 43.39B
Weighted average by Cap. +0.12%-0.84%+58.77%+129.91%
Logo Genkyotex
GenKyoTex SA is a France-based company involved in the biotechnology sector. The Company focuses on the development of therapies based on selective inhibition of nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes, which cause a range of disease processes, such as fibrosis, inflammation, pain processing, cancer development and neurodegeneration. The Company's pipeline includes GKT831, a NOX inhibitor aimed at primary biliary cholangitis (PBC) and fibrosis; GKT771, a NOX inhibitor mainly aimed at inflammatory pain and angiogenesis, and other NOX inhibitors, which target at central nervous system (CNS), hearing loss and oncology.
Employees
-